Cian Healthcare Limited has announced significant changes to its board composition following a board meeting held on March 16, 2026. The pharmaceutical company, which holds ISO 9001:2015 and WHO GMP certifications, has made two key directorial appointments that will strengthen its leadership structure.

Board Meeting Outcomes

The Board of Directors convened for meeting CHL/BM/2025-26/01 on March 16, 2026, from 02:00 P.M. to 03:38 P.M. (IST). Based on recommendations from the Nomination and Remuneration Committee, the board approved two significant appointments:

Managing Director Appointment

Mr. Rajesh Jain's designation has been changed from Non-Executive Director to Managing Director for a tenure of 3 consecutive years commencing from March 16, 2026. He brings over two decades of extensive professional experience across pharmaceuticals, retail, wholesale, manufacturing, laboratory services, and marketing sectors.

Educational Qualifications:

• Master of Pharmacy degree from Punjab Technical University (2013)
• Bachelor of Pharmacy degree from University of Rajasthan (1995)
• Currently pursuing PhD in pharmaceutical sciences

Mr. Jain is recognized as a dynamic professional with significant expertise in project management and production optimization within the pharmaceutical industry. His broad industry exposure has enabled him to develop strong leadership capabilities and deep understanding of competitive market environments.

Woman Director Appointment

Ms. Simmi Soni has been appointed as an Additional Director in the category of Woman Non-Executive Director. She brings over 15 years of extensive experience in administration, logistics management, and export coordination within the food supplement and pharmaceutical manufacturing sector.

Professional Experience:

• Since 2009: Pivotal role in strengthening administrative frameworks
• Expertise in logistics operations and export management processes
• Extensive experience in manufacturing support operations and regulatory coordination
• Successfully overseen coordination of material movement and finished product distribution across domestic and international markets

Ms. Soni is recognized for her ability to streamline operational procedures, enhance process efficiency, and facilitate effective cross-functional collaboration across departments while ensuring compliance with regulatory requirements.

Regulatory Compliance

Both appointments comply with Regulation 30 of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015, and SEBI Master Circular No. HO/49/14/14(7)2025-CFDPOD2/1/3762/2026 dated January 30, 2026. The company has confirmed that neither director is debarred from holding office by SEBI or any other applicable authority.

Next Steps

Both appointments are subject to approval by shareholders at the company's ensuing General Meeting. Ms. Soni will hold office as Additional Director until the date of the next General Meeting, while both directors will be liable to retire by rotation in accordance with the Companies Act, 2013 provisions.

Cian Healthcare Limited has announced that its Board of Directors approved a revised Code of Practices and Procedures for Fair Disclosure of Unpublished Price Sensitive Information (UPSI) during a meeting held on March 16, 2026. The decision was communicated to BSE Limited through an official intimation pursuant to Regulation 8(2) of the Securities and Exchange Board of India (Prohibition of Insider Trading) Regulations 2015.

Board Meeting Outcome

The Board meeting (CHL/BM/2025-26/01) was conducted physically on March 16, 2026, where directors considered and approved the revised code. Company Secretary and Chief Compliance Officer Rachit Malhotra (Membership No.: A39894) signed the official communication, confirming the approval and submission of the revised code as Annexure-A to the stock exchange.

Key Features of the Revised Code

The comprehensive code establishes a structured framework for handling UPSI and ensures compliance with regulatory requirements. The document defines critical roles, including the Chief Investor Relations Officer (CIRO), who will be responsible for proper and timely dissemination of information and determination of whether particular information constitutes UPSI.

Principles of Fair Disclosure

The revised code outlines several key principles that the company must adhere to:

• Prompt dissemination of UPSI that would impact price discovery as soon as credible information becomes available
• Uniform and universal dissemination through stock exchanges and company website before releasing to media or analysts
• Handling all UPSI on a need-to-know basis with appropriate safeguards
• Ensuring employees do not respond to inquiries unless authorized by CIRO
• Making public announcements only after final or definitive decisions are taken

Compliance and Protection Measures

The code establishes comprehensive protection against retaliation and victimization for employees who file Voluntary Information Disclosure Forms with SEBI. It ensures that such employees cannot be discriminated against, discharged, terminated, or harassed for cooperating with regulatory authorities or participating in enforcement actions.

The company will maintain a structured digital database (SDD) containing details of UPSI sharing, including names of persons involved, their contact information, and relevant documentation. This database must be preserved for at least 8 years after completion of relevant transactions, with adequate systems to prevent tampering.

Regulatory Framework

The revised code incorporates definitions and requirements from multiple regulatory frameworks, including the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations 2015, Companies Act 2013, and related amendments. It establishes clear guidelines for determining legitimate purposes for sharing UPSI and ensures compliance with evolving regulatory requirements.

The audit committee will review compliance with the code at least once annually and verify the adequacy of internal control systems. The Board retains authority to amend the code as necessary to maintain compliance with applicable laws and regulations.

Source: None/Company/INE05BN01019/36ee858e-06f1-4f73-b078-8f658e101a1c.pdf